Novo Nordisk is expanding its use of AWS artificial intelligence tools across drug discovery, including AI agents for target identification, therapy design, and research workflows.
Under the agreement announced recently, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub at Novo Nordisk’s existing London facility, where AWS engineers and Novo Nordisk scientists will work directly with the pharmaceutical company’s data and research insights.
The London hub will bring Novo Nordisk R&D staff together with AWS engineers, AI specialists, applied scientists, and…
Read the full article at ARTIFICIALINTELLIGENCE-NEWS.COM
